米诺地尔搽剂最早由强生公司开发，2%规格于1988年在美国上市，5%规格于1997年在美国上市。该药 品2%规格用于治疗男性型脱发和斑秃;5%规格仅限男性使用，用于治疗男性型脱发和斑秃。2024年1 月，上药东英就该药品向国家药监局提出注册申请并获受理。截至公告日，公司针对该药品已投入的研 发费用约人民币656万元。 智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属上药东英(江苏)药业有限公司(简 称"上药东英")的米诺地尔搽剂收到国家药品监督管理局颁发的《药品注册证书》(证书编号： 2025S03530、2025S03531)，该药品获得批准生产。 ...

Core Insights - Shanghai has launched new national-level platforms aimed at enhancing innovation in traditional Chinese medicine and integrated circuit industries [1] Group 1: National Medical Innovation Platform - The National Medical Innovation Platform at Shanghai University of Traditional Chinese Medicine focuses on key technologies such as clinical advantage disease screening and intelligent pharmaceutical development [1] - Five leading companies in the industry, including Shanghai Pharmaceuticals and Shanghai Kaibao Pharmaceutical, have signed agreements to become the first batch of resident units [1] - The "Shanghai University of Traditional Chinese Medicine 7LAB Joint Laboratory" has been officially inaugurated [1] Group 2: Integrated Circuit Innovation Center - The "Integrated Circuit Packaging and Testing Talent Collaborative Innovation Center" is established through collaboration among government, academia, and enterprises [1] - This center aims to create a new high ground for talent integration in the integrated circuit industry [1] - The "Integrated Circuit Packaging and Testing Talent Integration Practice Base" has become a regional demonstration platform for industry-education collaboration, allowing students to engage in real production line environments and complete the entire process from design to testing [1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海醫藥集團股份有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02607 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 919,072,704 | RMB | | 1 RMB | | 919,072,704 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 919,072,704 | RMB | | 1 RMB | | 919,072,704 | | 2. 股份分類 | 普通股 | 股份類別 | ...

Group 1 - Shanghai Pharmaceuticals Holding Co., Ltd. announced that its subsidiary, Shanghai Hefu Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its Tramadol Hydrochloride Injection to pass the consistency evaluation of generic drugs [1][2] - The drug is primarily used for the treatment of moderate to severe pain and was originally developed by Grünenthal GmbH, first launched in Germany in 1977 [3] - As of the announcement date, the company has invested approximately RMB 1.52 million in research and development for this drug's consistency evaluation [3] Group 2 - According to the IQVIA database, the total procurement amount for Tramadol Hydrochloride Injection in hospitals across mainland China in 2024 was RMB 614.53 million [4] - The approval for consistency evaluation is expected to enhance the market competitiveness of Shanghai Hefu's Tramadol Hydrochloride Injection and expand its market share [5] - The company aims to leverage the experience gained from this evaluation for future product evaluations [5]

Core Viewpoint - The governance structure of listed companies is undergoing a significant transformation driven by the new Company Law and accompanying regulations from the China Securities Regulatory Commission (CSRC) [1][2] Regulatory Policy Support - The transformation is initiated by the revised Company Law, effective from July 1, 2024, allowing companies to establish an audit committee under the board of directors to assume the functions of the supervisory board, eliminating the need for a supervisory board [2] - The CSRC has issued several supporting policies to align with the new Company Law, including guidelines for company charters and shareholder meetings, with a final adjustment deadline set for January 1, 2026 [2] - Major pharmaceutical companies such as Shanghai Pharmaceuticals, Baiyunshan, and Sinopharm have announced amendments to their company charters to abolish the supervisory board [2] Streamlined Governance Structure - The cancellation of the supervisory board aims to optimize the governance structure through the professional advantages of the audit committee, enhancing operational efficiency [3] - The overlap in functions between the supervisory board and the audit committee has led to resource waste and increased communication costs; consolidating these functions is expected to speed up decision-making and align supervision with actual operations [3] - The audit committee's professional adaptability is particularly crucial in the fast-evolving and highly regulated pharmaceutical industry, allowing for better management of financial conditions, compliance, production quality, and sales risks [3] Enhanced Substantive Supervision - The governance structure change aims to shift corporate supervision from "formal compliance" to "substantive effectiveness," with the audit committee playing a key role in ensuring financial integrity and risk management [4] - A well-staffed audit committee can rigorously oversee financial conditions and internal controls, providing reliable information for investors and promoting sustainable corporate development [4] - The audit committee is expected to proactively identify and address potential risks, particularly in areas like technological innovation and market expansion within the pharmaceutical sector [4] Future Goals - The abolition of the supervisory board is just the starting point; the core goal is to establish a high-level, risk-matched supervisory system [5] - As the audit committee continues to improve in terms of talent composition and operational mechanisms, pharmaceutical companies are expected to enhance compliance and unleash innovation potential, contributing to high-quality industry development and public health initiatives [5]

Group 1 - Jianbang Co., Ltd. plans to repurchase shares using self-owned funds between 15 million and 30 million yuan, with a maximum price of 38 yuan per share [1] - Yatong Precision Engineering's investment in a private equity fund has been terminated due to failure to complete the agreed investment, leading to the fund's dissolution [1] - China Storage Co., Ltd. intends to invest 1.129 billion yuan in the Sanjiang Port project, with its wholly-owned subsidiary contributing 500 million yuan to establish a project company [2] Group 2 - Guangxin Co., Ltd. plans to inject assets worth 4.383 billion yuan into its wholly-owned subsidiary, increasing its registered capital from 10 million to 20 million yuan [3] - Jiangxin Home plans to use up to 3 billion yuan of idle self-owned funds for cash management in low-risk financial products [4] - Huangshan Tourism intends to lease part of the Huangshan scenic area for 1.27 billion yuan over a 10-year period [5] Group 3 - Jilin Expressway's general manager has resigned due to work adjustments [6] - Guoyao Modern's subsidiary has received a drug registration certificate for hydromorphone hydrochloride injection, suitable for pain management [8] - Hangya Technology plans to invest up to 70 million USD to establish subsidiaries in Singapore and Malaysia [10] Group 4 - ST Sailong's subsidiary has received approval for the listing of two chemical raw materials [11] - Shanghai Pharmaceuticals' tramadol hydrochloride injection has passed the consistency evaluation for generic drugs [12] - Yubang Electric has obtained a laboratory accreditation certificate from CNAS, indicating its testing capabilities [14] Group 5 - ST Lifang's stock will be subject to delisting risk warning starting December 1 due to administrative penalties [15] - Zhejiang Longsheng is investing 200 million yuan in a private equity partnership focused on high-potential enterprises [15] - Huayang Co., Ltd.'s subsidiary has obtained safety production permits, allowing it to commence production [16] Group 6 - Xujie Electric has won a bid for a State Grid project worth 1.518 billion yuan [17] - Pinggao Electric and its subsidiaries have collectively won a State Grid project worth approximately 773 million yuan [17] - ST Lanhua's subsidiary has entered the trial production phase for a juice beverage project with a total investment of up to 65 million yuan [18] Group 7 - Huakong Saige has terminated its stock issuance plan due to various considerations [19] - Yatong Co., Ltd. plans to invest 36 million yuan to establish a joint venture in renewable energy [20] - Warner Pharmaceuticals has received a drug registration certificate for a new inhalation solution for COPD patients [21] Group 8 - Demais has raised the upper limit for its share repurchase price to 45 yuan per share [22] - China West Electric's subsidiaries have collectively won a State Grid procurement project worth approximately 2.98 billion yuan [22] - Changan Automobile's joint venture has submitted a listing application to the Hong Kong Stock Exchange [23] Group 9 - Yinlun Co., Ltd. plans to invest approximately 133 million yuan to acquire a controlling stake in Shenzhen Deep Blue Electronics [24] - Zhongfu Information intends to increase its wholly-owned subsidiary's capital by 380 million yuan [24] - Financial Street's major shareholder has reduced its stake by 0.25% [25] Group 10 - Audiwei has formally submitted an application for H-share listing [26] - Zhongcai Technology's private placement application has been accepted by the Shenzhen Stock Exchange [27] - Haowei Group's subsidiary plans to invest 200 million yuan in a private equity fund focused on semiconductor investments [28] Group 11 - Jinkai New Energy is planning to transfer 51% of its subsidiary's equity to introduce strategic investors [31] - Huafeng Technology has reduced its fundraising target for a private placement to no more than 972 million yuan [32] - Mindray Medical's chairman plans to increase his stake in the company by 200 million yuan [33] Group 12 - Zhongman Petroleum's shareholders plan to reduce their holdings by up to 3% [35] - Innovation New Materials' shareholder intends to reduce their stake by up to 1% [37] - Guangdong Construction has signed a framework agreement to establish a quality testing base in Linzhi Economic Development Zone [39]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd., has passed the consistency evaluation for Tramadol Hydrochloride Injection, which is primarily used for treating moderate to severe pain [1] Summary by Categories Product Development - The company has invested approximately RMB 1.52 million in the research and development of this drug for the consistency evaluation [1] Market Impact - Products that pass the consistency evaluation will receive greater support in areas such as medical insurance payments and procurement by medical institutions, which is expected to help expand the market share of this drug and enhance its market competitiveness [1] Risks and Uncertainties - There is a possibility that the sales of this drug may not meet expectations, indicating significant uncertainty regarding its market performance [1]

Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd. (referred to as "Hefeng"), has received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration for its Tramadol Hydrochloride Injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The Tramadol Hydrochloride Injection is primarily used for the treatment of moderate to severe pain [1]

Core Viewpoint - Shanghai Pharmaceuticals (02607) announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd., received a notification from the National Medical Products Administration regarding the approval of the supplementary application for Tramadol Hydrochloride Injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1: Product Approval and Market Context - Tramadol Hydrochloride Injection is primarily used for the treatment of moderate to severe pain and was developed by Grünenthal GmbH, first launched in Germany in 1977 [1] - The supplementary application for the consistency evaluation was submitted to the National Medical Products Administration in August 2024 and has been accepted [1] - As of the announcement date, the company has invested approximately RMB 1.52 million in research and development for this product's consistency evaluation [1] Group 2: Competitive Landscape - Major domestic manufacturers of Tramadol Hydrochloride Injection in China include Ruiyang Pharmaceutical Co., Ltd., Shijiazhuang Yiling Pharmaceutical Co., Ltd., Jiangsu Jiuxu Pharmaceutical Co., Ltd., and North China Pharmaceutical Co., Ltd. [1] - According to the IQVIA database, the procurement amount for Tramadol Hydrochloride Injection in hospitals in mainland China for 2024 is RMB 614.53 million [1]

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 上海医药集团股份有限公司 关于盐酸曲马多注射液通过仿制药一致性评价的公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海医药集团股份有限公司关于盐酸曲马多注射液通过仿制药一致性评价的公告》 僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 11 月 29 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文 ...